Industry

Zenkuda superior to sham in phase 3 diabetic retinopathy study

Healio Ophthalmology4h ago1 min read

Zenkuda demonstrated superiority over sham in patients with diabetic retinopathy in the phase 3 GLOW2 study, according to a press release from Kodiak Sciences.In the confirmatory study, patients with proliferative diabetic retinopathy and mild diabetic macular edema and patients with moderately severe to severe diabetic retinopathy were randomly assigned to receive Zenkuda (tarcocimab tedromer) intravitreal injection (130 patients) or sham injection (125 patients), with dosing at baseline and at weeks 4, 8, 20 and 44. By the end of the study, all patients were on a 6-month dosing interval.At

Read full article on Healio Ophthalmology

AI Summary

Quick Take

Kodiak Sciences’ Zenkuda (tarcocimab tedromer) met its primary endpoint in the Phase 3 GLOW2 study, demonstrating statistically significant superiority over sham injections for patients with moderately severe to severe diabetic retinopathy. Crucially, the trial successfully transitioned all treated patients to an extended six-month dosing interval by the end of the study period while maintaining efficacy.

Why It Matters

The primary challenge in treating non-proliferative diabetic retinopathy (NPDR) is the high treatment burden of current anti-VEGF therapies, which often leads to 'watchful waiting' rather than active intervention. Tarcocimab tedromer utilizes a unique biopolymer conjugate platform designed for extended intraocular durability. If a twice-yearly injection schedule proves effective in real-world settings, it could fundamentally shift the standard of care toward earlier, preventative treatment of diabetic eye disease before vision-threatening complications like macular edema or neovascularization occur.

Key Findings

Zenkuda (tarcocimab tedromer) demonstrated superiority over sham in patients with moderately severe to severe NPDR and PDR with mild DME.
The study enrolled 255 patients, randomized to receive either Zenkuda (n=130) or sham (n=125).
Active treatment was administered at baseline and weeks 4, 8, 20, and 44.
By the conclusion of the study, 100% of patients in the Zenkuda arm were successfully maintained on a 6-month dosing interval.
The GLOW2 study serves as a confirmatory trial for the efficacy of tarcocimab in diabetic retinopathy populations.

Study Snapshot

Design

Phase 3, randomized, sham-controlled, confirmatory study

Population

Patients with moderately severe to severe NPDR or PDR with mild DME

Sample Size

255 patients

Practice Implications

Retina specialists should note the potential for a 24-week treatment interval, which is significantly longer than current standard-of-care anti-VEGF agents. This drug could be particularly relevant for high-risk NPDR patients who are non-compliant with frequent visits or those who wish to avoid the risks and inconvenience of monthly or bimonthly injections.

Who's Affected

Retina SpecialistsOphthalmologistsDiabetic Patients

What's Next

Following these positive Phase 3 results, Kodiak Sciences is expected to proceed with regulatory submission for Zenkuda. Clinicians should watch for upcoming data presentations regarding the specific percentage of patients achieving two-step or greater improvement on the Diabetic Retinopathy Severity Scale (DRSS).

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.